Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer

Clinical Cancer Research

Volumn 10, Issue 18 I, 2004, Pages 6039-6046

  Ferrucci, Pier Francesco ^a   Rabascio, Cristina ^a   Mazzetta, Chiara ^a   Cocorocchio, Emilia ^a   Agazzi, Alberto ^a   Vanazzi, Anna ^a   Cinieri, Saverio ^a   Peccatori, Fedro A ^a   Paolucci, Mara ^a   Bertolini, Francesco ^a   Martinelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL MARKER; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; MAMMAGLOBIN; MASPIN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CELL LINE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ERROR; DRUG MEGADOSE; EPITHELIUM CELL; EVALUATION; FEMALE; FOLLOW UP; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HYBRIDIZATION; INCIDENCE; ISOTOPE LABELING; LEUKAPHERESIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR CELL;

ADULT; AGED; BREAST NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; KERATINS; KI-67 ANTIGEN; LEUKAPHERESIS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME; UTEROGLOBIN;

EID: 4644338360     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0453     Document Type: Article

References (37)

1. Fisher ER. Prognostic and therapeutic significance of pathological features of breast cancer. Natl Cancer Inst Monogr 1986;1:29-34.
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapyfor early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-42.
3. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-1467.
4. Mansi JL, Berger U, McDonnel T, et al. The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol 1989;7:445-9.
5. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991;9:1749-56.
6. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst (Bethesda) 1996;88:1652-8.
7. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000;342:525-33.
8. Fields KK, Elfenbein GJ, Trudeau WL, et al. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996;14:1868-76.
9. Moss TJ, Cooper B, Kennedy MJ, et al. The prognostic value of immunocytochemical (ICC) analysis on bone marrow (BM) and stem cell products (PBSC) taken from patients with stage FV cancer undergoing autologous transplant (ABMT) therapy [abstract 90a]. Proc Am Soc Clin Oncol 1997;16.
10. Funke I, Schraut W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol 1998;16:557-66.
11. Franklin WA, Glaspy J, Pflaumer SM, et al. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. Blood 1999;1:340-7.
12. Sharp JC, Kessinger A, Vaughan WP, et al. Detection and clinical significance of minimal TCC of peripheral blood stem cells harvests [abstract 92]. Int J Cell Cloning 1992;10(Suppl 1).
13. Chabannon C, Olivero S, Viret F, et al. Detection of epithelial cells in hematopoietic organs of patients with breast cancer. Physiopathological significance and clinical consequences. Acta Haematol 2001;105:166-71.
14. Brugger W, Bross KJ, Glatt M, et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994;83:636-40.
15. Ross A, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993;82:2605-10.
16. Brenner MK, Rill DR, Moen RC, et al. Gene marking and autologous bone marrow transplantation. Ann NY Acad Sci 1994;716:204-14.
17. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 2000;6:196-9.
18. Zhu Z, Anisowicz A, Hendrix MJC, et al. Maspin, a serpin with tumor suppressing activity in human mammary epithelial cells. Science (Wash DC) 1994;263:526-9.
19. Mohsin SK, Zhang M, Clark GM, Craig Allred D. Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol 2003;199:432-5.
20. Bieche I, Girault I, Sabourin JC, et al. Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomas. Br J Cancer 2003;88:863-70.
21. Ferrucci PF, Rabascio C, Corsini C, et al. Expression of the maspin gene, a recently discovered antiangiogenesis tumor suppressor, protects high risk breast cancer patients from relapse. Ann Oncol 2000;1(Suppl 4):22.
22. Maass N, Nagasaki K, Ziebart M, Mundhenke C, Jonat W. Expression and regulation of tumor suppressor gene maspin in breast cancer. Clin Breast Cancer 2002;3:281-7.
23. Umekita Y, Yoshida H. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma. Histopathology 2003;42:541-5.
24. Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996;56:860-5.
25. Watson MA, Dintzis S, Darrow CM, et al. Mammaglobin expression in primary, metastatic and occult breast cancer. Cancer Res 1996;59:3028-31.
26. Lin YC, Chen SC, Hsueh S, et al. Lack of correlation between expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients. Cancer Sci 2003;94:99-102.
27. Silva AL, Tome MJ, Correia AE, Passos-Coelho JL. Human mammaglobin RT-PCR assay for detection of occult breast cancer cells in hematopoietic products. Ann Oncol 2002;13:422-9.
28. Bossolasco P, Ricci C, Farina G, et al. Detection of micrometastatic cells in breast cancer by RT-pCR for the mammaglobin gene. Cancer Detect Prev 2002;26:60-3.
29. Leone F, Perissinotto E, Viale A, et al. Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction. Bone Marrow Transplant 2001;27:517-23.
30. Moschinski LC, Trudeau VL, Fields KK, Elfenbein GJ. High sensitivity detection of minimal residual breast carcinoma using the polymerase chain reaction and primers for cytokeratin 19. Diagn Mol Pat 1996;5:173-80.
31. Zach O, Kasparu H, Krieger O, et al. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol 1999;17:2015-9.
32. Luppi M, Moruzzelli M, Bandieri E, et al. Sensitive detection of circulating breast cancer cells by reverse Transcriptase polymerase chain reaction of maspin gene. Ann Oncol 1996;7:619-24.
33. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
34. S-PLUS 2000 Professional Release 2. Copyright (c) 1988-1999 MathSoft, Inc.
35. Patriarca F, Sacco C, Sperotto A, et al. Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy. Bone Marrow Transplant 2003;31:789-94.
36. Syme R, Stewart D, Rodriguez-Galvez M, et al. Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT). Bone Marrow Transplant 2003;32:307-11.
37. Kasimir-Bauer S, Mayer S, Bojko P, et al. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy. Clin Cancer Res 2001;7:1582-9.